The growing incidents of cryptococcosis in immuno-compromised patients have created a need for novel drug therapies capable of eradicating the disease. The peptide-based drug therapy offers many advantages over the traditional therapeutic agents, which has been exploited in the present study by synthesizing a series of hexapeptides that exhibits promising activity against a panel of Gram-negative and Gram-positive bacteria and various pathogenic fungal strains; the most exemplary activity was observed against Cryptococcus neoformans. The peptides 3, 24, 32 and 36 displayed potent anticryptococcal activity (IC50 = 0.4-0.46 μg/mL, MIC = 0.63-1.25 μg/mL, MFC = 0.63-1.25 μg/mL), and stability under proteolytic conditions. Besides this, several other peptides displayed promising inhibition of pathogenic bacteria. The prominent ones include peptides 18-20, and 26 that exhibited IC50 values ranged between 2.1 and 3.6 μg/mL, MICs of 5-20 μg/mL and MBCs of 10-20 μg/mL against Staphylococcus aureus and methicillin-resistant S. aureus. The detailed mechanistic study on selected peptides demonstrated absolute selectivity towards the bacterial membranes and fungal cells by causing perturbations in the cell membranes, confirmed by the scanning electron microscopy and transmission electron microscopy studies.
Keywords: Amphiphilic hexapeptides; Anticryptococcal; Electron microscopy; Proteolysis; Solid phase peptide synthesis.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.